What is Hypha Labs's earnings per share (EPS)?

Hypha Labs (FUNI) reported diluted earnings per share of $-0.02 for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Hypha Labs Financials

FUNI

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE September

This page shows Hypha Labs (FUNI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FUNI FY2025 2026-05-15

Hypha Labs is being sustained by external financing while operating cash burn persists against a negative-equity balance sheet.

From FY2023 to FY2025, cash fell from $271K to $38K even though the share count rose sharply. In FY2025, financing inflow of $360K almost matched operating cash burn of -$380K, implying fresh capital was largely used to keep the business running rather than rebuild liquidity.

Short-term liquidity remains extremely thin: FY2025 cash was just $38K against current liabilities of $1.12M. That gap suggests the operating cycle is being carried by short-term claimants rather than by an internal cash cushion, and the weak working-capital position seen in FY2024 did not meaningfully heal in FY2025.

Capital intensity is not the main drain: FY2025 capex was only $33K while free cash flow was -$413K. Because free cash flow nearly mirrors operating cash flow, the shortfall appears tied more to the ongoing cost base and financing needs than to expansion spending, even though the burn eased from FY2024.

Financial Health Signals

Financial Profile 10/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Hypha Labs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Hypha Labs has a moderate D/E ratio of -1.17. This balance of debt and equity financing earns a leverage score of 57/100.

Liquidity

Hypha Labs's current ratio of 0.29 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

$-0.02

YoY-100.0%

Hypha Labs earned $-0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 100.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$413K

YoY+61.1%

Hypha Labs generated -$413K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 61.1% from the prior year.

Cash & Debt

$38K

YoY-58.2%

5Y CAGR-14.4%

10Y CAGR-22.4%

Hypha Labs held $38K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

145M

YoY+17.9%

5Y CAGR+20.0%

10Y CAGR+26.6%

Hypha Labs had 145M shares outstanding in fiscal year 2025. This represents an increase of 17.9% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$33K

YoY+19.2%

5Y CAGR-25.2%

10Y CAGR-31.5%

Hypha Labs invested $33K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 19.2% from the prior year.

FUNI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	$2.7M+7.8%	$2.5M-2.7%	$2.6M
Cost of Revenue	N/A	N/A	N/A	$1.6M-8.6%	$1.8M+0.6%	$1.8M
Gross Profit	N/A	N/A	N/A	$1.1M+49.0%	$715K-10.1%	$796K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$1.4M+50.1%	$944K+813.6%	$103K-79.2%	$496K-46.9%	$934K-37.0%	$1.5M
Operating Income	N/A	-$1.8M-317.7%	-$437K+62.0%	-$1.2M-48.9%	-$772K+64.8%	-$2.2M
Interest Expense	$106K-47.4%	$202K-44.6%	$364K+48.9%	$245K+68.7%	$145K-2.1%	$148K
Income Tax	N/A	$14K	N/A	N/A	N/A	N/A
Net Income	N/A	-$785K-418.3%	$247K+112.0%	-$2.1M-199.7%	-$687K+70.3%	-$2.3M
EPS (Diluted)	$-0.02-100.0%	$-0.01	$0.00+100.0%	$-0.03	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$114K-38.5%	$186K	N/A	$82K-14.4%	$95K-91.0%	$1.1M	N/A	$486K
Operating Income	-$420K+11.5%	-$475K	N/A	-$536K+19.9%	-$669K	N/A	N/A	-$614K
Interest Expense	$101K+116.1%	$47K	N/A	$26K+14.7%	$23K+1.3%	$22K	N/A	$22K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$23K
Net Income	-$521K+0.1%	-$522K	N/A	-$562K+12.4%	-$642K	N/A	N/A	-$707K
EPS (Diluted)	$0.00	$0.00	N/A	$0.00	$0.00+100.0%	$-0.01	N/A	$-0.01

FUNI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$409K-17.1%	$494K-65.0%	$1.4M+5.2%	$1.3M-29.0%	$1.9M+5.6%	$1.8M
Current Assets	$321K-21.9%	$410K-46.4%	$766K+36.2%	$562K-32.0%	$827K+108.2%	$397K
Cash & Equivalents	$38K-58.2%	$91K-66.4%	$271K+382.5%	$56K-81.0%	$296K+257.6%	$83K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$335K+55.9%	$215K-11.3%	$242K
Goodwill	N/A	N/A	N/A	N/A	N/A	$593K
Total Liabilities	$2.8M+62.2%	$1.8M-51.5%	$3.6M-11.5%	$4.1M+38.8%	$2.9M+2.2%	$2.9M
Current Liabilities	$1.1M-19.7%	$1.4M-55.4%	$3.1M+5.7%	$3.0M+46.6%	$2.0M+160.7%	$773K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$2.4M-93.3%	-$1.3M+42.8%	-$2.2M+19.6%	-$2.7M-160.4%	-$1.1M+3.3%	-$1.1M
Retained Earnings	-$23.6M-15.1%	-$20.5M-4.0%	-$19.8M+1.2%	-$20.0M-11.5%	-$18.0M-4.0%	-$17.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$160K-59.2%	$392K-4.3%	$409K-9.9%	$454K+76.7%	$257K-0.6%	$259K-47.6%	$494K-34.4%	$752K
Current Assets	$96K-69.4%	$315K-1.9%	$321K-5.8%	$340K+82.1%	$187K+5.2%	$178K-56.7%	$410K-44.2%	$735K
Cash & Equivalents	$82K+91.8%	$43K+12.4%	$38K-74.1%	$147K+597.8%	$21K-42.3%	$37K-59.9%	$91K-82.1%	$509K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.3M+6.5%	$3.1M+8.1%	$2.8M+12.9%	$2.5M+21.5%	$2.1M+13.8%	$1.8M+3.9%	$1.8M+0.6%	$1.7M
Current Liabilities	$1.4M+8.6%	$1.3M+18.0%	$1.1M-48.8%	$2.2M+26.1%	$1.7M+17.7%	$1.5M+5.7%	$1.4M-1.1%	$1.4M
Long-Term Debt	$1.8M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$3.1M-16.1%	-$2.7M-10.2%	-$2.4M-17.9%	-$2.1M-13.7%	-$1.8M-16.2%	-$1.6M-24.1%	-$1.3M-27.2%	-$990K
Retained Earnings	-$24.7M-2.2%	-$24.2M-2.2%	-$23.6M-2.4%	-$23.1M-2.5%	-$22.5M-2.9%	-$21.9M-6.5%	-$20.5M-2.3%	-$20.1M

FUNI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$380K+63.2%	-$1.0M-1018.8%	$113K+160.9%	-$185K-35.9%	-$136K+79.8%	-$672K
Capital Expenditures	$33K+19.2%	$28K	N/A	$18K-68.5%	$56K-60.2%	$141K
Free Cash Flow	-$413K+61.1%	-$1.1M	N/A	-$203K-5.4%	-$192K+76.4%	-$813K
Investing Cash Flow	-$33K-101.5%	$2.1M+714.9%	$263K+139.9%	-$660K-130.7%	-$286K+16.1%	-$341K
Financing Cash Flow	$360K+127.9%	-$1.3M-702.2%	-$161K-126.6%	$605K-4.7%	$635K-17.7%	$772K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$51K+66.3%	-$150K+52.3%	-$315K-1252.1%	-$23K+30.8%	-$34K-323.3%	-$8K+98.2%	-$436K+18.8%	-$537K
Capital Expenditures	$2K	N/A	$31K	$0+100.0%	-$1-100.1%	$2K-83.0%	$10K	N/A
Free Cash Flow	-$52K	N/A	-$346K-1386.2%	-$23K+30.8%	-$34K-247.6%	-$10K+97.8%	-$446K	N/A
Investing Cash Flow	-$2K	N/A	-$31K	$0-100.0%	$1+100.1%	-$2K-103.6%	$48K+374.7%	-$17K
Financing Cash Flow	$90K-41.9%	$155K-34.7%	$237K+58.8%	$149K+722.3%	$18K+140.5%	-$45K-49.7%	-$30K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

FUNI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	39.5%+10.9pp	28.6%-2.3pp	30.9%
Operating Margin	N/A	N/A	N/A	-42.6%-11.8pp	-30.9%+54.3pp	-85.2%
Net Margin	N/A	N/A	N/A	-76.2%-48.8pp	-27.4%+62.3pp	-89.7%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-159.1%-176.6pp	17.5%+171.0pp	-153.5%-117.2pp	-36.4%+92.8pp	-129.1%
Current Ratio	0.290.0	0.29+0.0	0.25+0.1	0.19-0.2	0.41-0.1	0.51
Debt-to-Equity	-1.17+0.2	-1.39+0.2	-1.64-0.2	-1.49+1.3	-2.79-0.2	-2.64
FCF Margin	N/A	N/A	N/A	-7.5%+0.2pp	-7.7%+23.9pp	-31.6%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-326.1%-192.9pp	-133.2%	N/A	-123.8%+126.0pp	-249.8%	N/A	N/A	-94.0%
Current Ratio	0.07-0.2	0.24-0.0	0.29+0.1	0.16+0.0	0.11-0.0	0.12-0.2	0.29-0.2	0.52
Debt-to-Equity	-0.59+0.6	-1.15+0.0	-1.17+0.1	-1.22-0.1	-1.14+0.0	-1.17+0.2	-1.39+0.4	-1.76
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$2.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.29), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Imd Companies ICBU

$3.8M

Rennova Health RNVA

$4.3M

Interpace Biosciences Inc IDXG

$50.4M

Stagezero Life SZLSF

$3.6M

Leveljump Health JMPHF

$34.7M

Frequently Asked Questions

What is Hypha Labs's free cash flow?

Hypha Labs (FUNI) generated -$413K in free cash flow during fiscal year 2025. This represents a 61.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Hypha Labs's operating cash flow?

Hypha Labs (FUNI) generated -$380K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Hypha Labs's total assets?

Hypha Labs (FUNI) had $409K in total assets as of fiscal year 2025, including both current and long-term assets.

What are Hypha Labs's capital expenditures?

Hypha Labs (FUNI) invested $33K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Hypha Labs have outstanding?

Hypha Labs (FUNI) had 145M shares outstanding as of fiscal year 2025.

What is Hypha Labs's current ratio?

Hypha Labs (FUNI) had a current ratio of 0.29 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Hypha Labs's debt-to-equity ratio?

Hypha Labs (FUNI) had a debt-to-equity ratio of -1.17 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Hypha Labs's cash runway?

Based on fiscal year 2025 data, Hypha Labs (FUNI) had $38K in cash against an annual operating cash burn of $380K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Hypha Labs's debt-to-equity ratio negative or unusual?

Hypha Labs (FUNI) has negative shareholder equity of -$2.4M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

How financially healthy is Hypha Labs?

Hypha Labs (FUNI) scores 10 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.